Despite depressive disorders and antidepressant treatment being common among older (65+ years) and very old (85+ years) adults, Reference Giovannini, Onder, van der Roest, Topinkova, Gindin and Cipriani1,Reference Lenze and Ajam Oughli2 the associations among depressive disorders, there has been little research on antidepressant use and mortality among very old adults, or differences between men and women in this regard. Studies have shown that depressive disorders increase the risk of premature mortality among older adults (65+ years), Reference Péquignot, Dufouil, Pérès, Artero, Tzourio and Empana3,Reference Schulz, Beach, Ives, Martire, Ariyo and Kop4 with some identifying an increased mortality risk specifically among older men. Reference Barry and Zdanys5,Reference Cai, Mueller, Shetty, Perera and Stewart6 A previous study found that very old adults with depressive disorders reported poorer well-being and had higher 1-year mortality rates compared with very old adults with no depressive disorder; Reference Bergdahl, Gustavsson, Kallin, Von Heideken Wågert, Lundman and Bucht7 however, this study did not explore potential gender-based differences.
Antidepressant treatment among older adults may lead to adverse side-effects owing to drug–drug interactions and medical comorbidities. Reference Sobieraj, Martinez, Hernandez, Coleman, Ross and Berg8,Reference Taylor9 Some studies have found no increased risk of mortality associated with antidepressant treatment among older adults, Reference Kollhorst, Jobski, Krappweis, Schink, Garbe and Schmedt10 including those with dementia, Reference Enache, Fereshtehnejad, Cermakova, Garcia-Ptacek, Kåreholt and Johnell11 whereas others have shown an increased risk of mortality. Reference Coupland, Dhiman, Morriss, Arthur, Barton and Hippisley-Cox12,Reference Santandreu, Caballero, Gómez-Serranillos and González-Burgos13 One study of antidepressant treatment and mortality specifically among very old adults showed that although antidepressant treatment was not independently associated with an increased risk of mortality, gender-based differences may exist. Reference Boström, Hörnsten, Brännström, Conradsson, Nordström and Allard14 It is also important to note that previous studies have used different methodologies, and one that applied advanced statistical matching methods found no increased mortality risk among older adults (65+ years) with antidepressant treatment. Reference Kollhorst, Jobski, Krappweis, Schink, Garbe and Schmedt10 The scarcity of studies on this topic may be due to the current underrepresentation of very old adults in drug and clinical trials, as numerous studies tend to exclude this demographic group. Reference Lenze and Ajam Oughli2,Reference Bourgeois, Orenstein, Ballakur, Mandl and Ioannidis15
A recent Swedish study found increasing prevalence rates of depressive disorders among very old adults, with 29.7% of 85-year-olds, 47.5% of 90-year-olds and 53.6% of those over 95 years old having a depressive disorder in 2015–2017. Reference Corneliusson, Gustafson and Olofsson16 As the number of very old adults is projected to rise from 143 million in 2019 to 426 million by 2050, 17 it is both essential and urgent to explore and address factors related to depressive disorders in this population to ensure good quality of life and adequate allocation of resources. The aim of the present study was to investigate the impact of depressive disorders and antidepressant treatment on 2-year mortality among very old adults and to explore any differences between men and women.
Method
Settings and participants
This study was based on home visits performed in the Umeå 85+/Gerontological Regional Database (GERDA) study, a population-based, cross-sectional and longitudinal study. The GERDA study aims to increase knowledge of very old adults’ health and living conditions and provide data for planning and support of their care (www.gerdacentre.com). Participants were selected on the basis of age and place of residence. In the regions listed below, every other 85-year-old, every 90-year-old, and all those aged 95 years and older were asked to participate. The choice to select every other 85-year-old was made so that the groups would be equal in size. The names, addresses and civil registration numbers of all potential participants living in the areas were collected from the National Tax Board in Sweden and the Population Register Centre in Finland.
The study started in 2000 in Umeå, with rural communities added in 2002. Data collections were repeated every 5 years (2005–2007, 2010–2012 and 2015–2017). At each data collection, new participants were added, and previous participants who were still alive were also invited. Surviving participants from previous cohorts were included as unique cases in the subsequent cohorts. All collections used identical procedures and inclusion criteria. No exclusion criteria were used. Home visits were conducted in the city of Umeå in 2000, 2005, 2010 and 2015, as well as in five rural municipalities (Malå, Vilhelmina, Storuman, Sorsele and Dorotea) in 2002, 2007, 2012 and 2017. In Österbotten, Finland, the home visits were performed twice (2006 and 2011–2012). The city of Vaasa and the rural Korsholm municipality participated in both data collections, whereas the second data collection also included home visits in rural municipalities Malax and Korsnäs.
Eligible participants were approached by postal mail and provided with information about the study. Within 2 weeks, they were asked to provide their consent for participation by telephone, and a home visit was scheduled. During the home visits, consent was again confirmed. If the participants were cognitively impaired or could not consent, next of kin or caregivers were consulted. In addition, all participants were asked for consent for access to their medical journals. The participants could withdraw from the study without explanation or consequence.
Assessments
Trained professionals (nurses, medical students, physiotherapists and physicians) conducted structured interviews and performed physical assessments during the home visits. The interviews contained questions about sociodemographic factors such as living arrangements, marital status and years of education. Height and weight were measured with a calibrated scale and measuring stick, and body mass index was calculated. Impaired vision was defined as being unable to read 5 mm text from 30 cm with or without glasses. Impaired hearing was defined as being unable to hear a normal conversation from 1 m away with or without a hearing aid. The Mini-Mental State Examination (MMSE) was used to assess cognitive status. The MMSE consists of questions and tasks that assess various aspects of cognitive function, with scores in the range of 0–30; higher scores indicate better cognitive function, and a score below 24 may indicate cognitive impairment. Reference Folstein, Folstein and McHugh18 Dependency in activities of daily living was assessed using Barthel’s index. Scores on this index range from 0 to 20, with higher scores indicating greater independence. Reference Collin, Wade, Davies and Horne19
Assessments conducted during the home visits to evaluate potential depressive disorders included the Geriatric Depression Scale (GDS-15), the Philadelphia Geriatric Center Morale Scale (PGCMS), the Life Orientation Test (LOT), the Montgomery–Åsberg Depression Rating Scale (MADRS), and the Organic Brain Syndrome Scale (OBS). The interview protocol also included a question on whether the participants felt they were happy or unhappy, which was scored on a five-point Likert scale.
The GDS-15 consists of 15 questions used to assess various aspects of depressive symptoms. Reference Sheikh and Yesavage20 The questions are answered yes or no and scored either 1 or 0, and the total score is summed. Scores of 5 or above indicate degrees of depressive symptoms, with higher scores indicating a greater severity of depressive symptoms. Reference Sheikh and Yesavage20 The GDS-15 has been shown to be reliable for detecting depressive disorders in people over 85 years old with high sensitivity and specificity, as well as an internal reliability of α = 0.73. Reference Almeida and Almeida21,Reference Snellman, Hörnsten, Olofsson, Gustafson, Lövheim and Niklasson22 It has also been shown to be reliable for use among very old adults with MMSE scores of 10 or more. Reference Conradsson, Rosendahl, Littbrand, Gustafson, Olofsson and Lövheim23
The PGCMS is designed to assess an individual’s morale, including emotional well-being, satisfaction in life and overall well-being. Reference Lawton24 The PGCMS consists of 17 items, answered yes or no. Reference Lawton24 The scale has been used in research to assess morale in older adults and as a tool for identifying individuals at risk of developing depression. Reference Lawton24,Reference Niklasson, Näsman, Nyqvist, Conradsson, Olofsson and Lövheim25
The LOT is a tool designed to measure a person’s overall life satisfaction, using questions concerning feelings about the future, loneliness and will to live, including the question ‘are you depressed?’. Reference Fagerström26 The Revised LOT (LOT-R) is considered to be reliable and easily understood by older adults. Reference Fagerström26
The MADRS is a clinical assessment tool designed to measure the severity of depression, on the basis of the respondent’s self-report and clinical observations. Reference Snaith, Harrop, Newby and Teale27 It contains questions about the core symptoms of depression. Each item is scored from 0 to 6, with higher scores indicating more severe depressive symptoms. The MADRS is most commonly used for evaluating treatment response and effectiveness of interventions for depression. Reference Müller28 Here, it was used only when the interviewer was a physician or medical student trained to use the scale.
The OBS is an observational tool used to assess cognitive function and detect organic brain dysfunction. Reference Jensen, Dehlin and Gustafson29 The OBS evaluates the individual’s clinical state in the past month, including emotional and behavioural symptoms. In addition, one item concerns the degree of depressed mood based on the overall impression during the full interview, rated from 0 to 3. Reference Björkelund, Larsson, Gustafson and Andersson30
Information on medical conditions, prescribed medications and diagnoses was collected from the participants’ medical journals and during the home visits. Prescribed medications were reviewed with the participants during the home visit, and only medications that the participants confirmed that they used were registered as used medications in this study. The participants’ medical records were reviewed after consent had been obtained, and information was confirmed in person by either the participant or a relative and/or caregiver. Relatives also contributed additional relevant information if applicable. For this study, response to antidepressant treatment was defined as having been prescribed antidepressants and scoring less than 5 on the GDS-15, whereas non-response was defined as having been prescribed antidepressants and having a GDS score equal to or greater than 5.
An experienced geriatrician (Y.G.) reviewed all medical records and diagnoses and set the diagnoses of depressive and dementia disorders in all cohorts in both Sweden and Finland according to the DSM-IV-TR. All available documentation, medical records and applicable assessments (GDS-15, PGCMS, LOS, MADRS, OBS and Barthel) were used. These DSM-IV-TR-based diagnoses of depressive disorders and dementia were consistently used in this study when referring to depressive disorders or dementia. The diagnostic procedure has been described in detail elsewhere. Reference Corneliusson, Gustafson and Olofsson16 Mortality records were collected from the death certificates of deceased participants, population registers or medical records. The sample for this study consisted of 2551 participants, of whom 918 participants had a diagnosis of a depressive disorder according to the DSM-IV-TR. 31 The STROBE guidelines were adhered to throughout this study. Reference von Elm, Altman, Egger, Pocock, Gotzsche and Vandenbroucke32
Statistical analysis
Descriptive statistics, including frequencies and means, were used to analyse the characteristics of the entire sample. Chi-squared test, Fisher’s exact test and t-test were used to assess differences between groups and means. We used logistic regression models to identify factors associated with depressive disorders and mortality in men and women, and Cox proportional hazards regressions to explore factors associated with time to death. Kaplan–Meier survival analyses were used to determine differences in survival between groups and to compare survival distributions. Statistical significance was defined as P < 0.05. IBM SPSS statistics version 29.0, for Windows (IBM Corporation, Armonk, NY, USA; https://www.ibm.com/products/spss-statistics) was used for the statistical analyses.
Ethical considerations
The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. All procedures involving human participants and/or patients were approved by the Regional Ethical Review Board of Umeå/Swedish Ethical Review Authority, Sweden (Dnr 99-326, 05-063M, 09-178M, 2015/296-31, 2021-00023) and the Ethics Committee of Vaasa Central Hospital (reg. nos. 05-87 and 10-54). All data have been stored in compliance with data regulation laws.
Results
Characteristics of the sample
The total sample consisted of 2551 participants, of whom 918 (36%) had a diagnosis of a depressive disorder. Women had higher rates of depressive disorders compared with men (39 v. 29%, P < 0.001) (Table 1). Women with depressive disorders were found to significantly differ from men with depressive disorders with respect to several demographic factors: the women were generally older and had fewer years of education compared with the men and were also more likely to be widowed and living alone (P < 0.001). In addition, women had higher rates of visual impairment (26.4 v. 16.9%, P = 0.01) and hypertension (75.3 v. 65.0%, P = 0.01) and were prescribed more medications than men (8.63 v. 7.38%, P < 0.001). Myocardial infarctions were more prevalent in men with depressive disorders compared with women with depressive disorders (20.4 v. 11.1%, P < 0.001) (Supplementary Table 1 available at https://doi.org/10.1192/bjp.2025.10344). A total of 913 participants had died within the 2-year period after inclusion in the study.
Table 1 Characteristics of participants with and without a depressive disorder

IQR, interquartile range; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; ADL, activities of daily living.
a. Bold text indicates statistical significance (P < 0.05).
Factors associated with depressive disorders in men and women
To explore factors associated with depressive disorders in men and women, we constructed a logistic regression model stratified by gender with the following variables: age, living alone, being a widow or widower, diabetes, heart failure, angina pectoris, previous stroke, dementia, hypertension, chronic lung disease, and vision and hearing impairment. In the univariate analyses, several of these variables showed significant associations with depressive disorders in men and women, as well as significant differences between men and women with or without depressive disorders (Supplementary Table 2). Living alone, dementia and heart failure were significantly associated with depressive disorders in both men and women, whereas diabetes was inversely associated with depressive disorders in both groups. Age, angina pectoris and visual impairment were associated with depressive disorders exclusively in women, whereas being a widower was associated with depressive disorders only in men (Supplementary Table 2).
Factors associated with death within 2 years after inclusion in men and women
To explore mortality within 2 years after inclusion in the study, we constructed a Cox regression model with the following variables: living alone, being a widow or widower, diabetes, heart failure, angina pectoris, previous stroke, dementia, hypertension, chronic lung disease, vision and hearing impairment, and depressive disorders. Cox regression analysis showed that age, dementia, heart failure and depressive disorders were statistically significant predictors of mortality in men, with a 24% increased risk of death among men with depressive disorders. Age, dementia, diabetes and chronic lung disease were significant predictors of mortality in women. Depressive disorders and time to death showed no significant independent association in women (Table 2).
Table 2 Results of the multivariate Cox regression model – factors associated with death within 2 years after inclusion in men and women

a. Bold text indicates statistical significance (P < 0.05).
Survival differences between participants with and without a depressive disorder, stratified by gender
Kaplan–Meier curves were constructed and used to compare survival rates between groups. Participants with a depressive disorder had higher mortality compared with those without a depressive disorder (log-rank P < 0.001), men with a depressive disorder had higher mortality compared with women with a depressive disorder (log-rank P = 0.004), men with a depressive disorder had higher mortality than men without depressive disorders (log-rank P < 0.001) and women with a depressive disorder had higher mortality than women without depressive disorders (log-rank P < 0.001) (Fig. 1). Complementary analysis of 1-year survival revealed similar trends, with men diagnosed with depressive disorders having approximately twice the risk of mortality of those without depressive disorders (log-rank P < 0.001).

Fig. 1 Two-year survival curves comparing participants with no depressive disorders versus those with depressive disorders. Results are presented for all participants with and without a depressive disorder, men and women with a depressive disorder, and in subgroups of women and men with and without a depressive disorder.
Participants with and without antidepressant treatment
Data on medication use were available for 907 of the 918 participants with a depressive disorder. Of these 907 participants, 485 individuals (53.5%) were treated with antidepressants, whereas 422 (46.5%) were not treated with antidepressants. According to our descriptive analyses of the differences between participants with and without antidepressant treatment, the treated group had a significantly lower mean age compared with the untreated group (90.2 v. 90.8%, P = 0.05). Previous stroke and dementia were significantly more prevalent in the treatment group (21.4 v. 14.5%, P = 0.01 and 62.1 v. 46.3%, P ≤ 0.001, respectively). Previous malignancy was the only diagnosis significantly more prevalent in the untreated group (20.0 v. 14.5%, P = 0.03) (Supplementary Table 3). Women tended to be treated with antidepressants more often than men (55 v. 47%), although the difference was not statistically significant (P = 0.077). Kaplan–Meier curves were constructed to compare survival rates between those who received antidepressant and those who did not, as well as between responders and non-responders to antidepressants. Mortality rates were significantly higher among participants with a depressive disorder and antidepressant treatment compared with those without (log-rank P = 0.006), in women with a depressive disorder and antidepressant treatment compared with those with a depressive disorder and no antidepressant treatment (log-rank P = 0.024), and in men with a depressive disorder and antidepressant treatment compared with men with a depressive disorder and no antidepressant treatment (log-rank P = 0.041) (Fig. 2). However, a complimentary analysis using Cox regression and adjusting for the variables shown in Table 2 found no independent association between antidepressant treatment and mortality (data not presented in tables).

Fig. 2 Two-year survival curves comparing those with depressive disorders and receiving antidepressant treatment. Results are presented for all participants with a depressive disorder with and without antidepressant treatment, and for subgroups of women and men.
Responders and non-responders to antidepressant treatment
Data on response to treatment with antidepressants were available for 283 participants. Of these participants, 125 (44.2%) were classified as non-responders to antidepressant treatment, whereas 158 (55.8%) were classified as responders. Descriptive analyses of the differences between responders and non-responders showed that responders were younger (89.4 v. 90.6 years of age, P = 0.02) and exhibited lower GDS-15 scores (2.45 v. 7.46, P < 0.001), indicating significant alleviation of depressive symptoms. No clinical characteristics were significantly predominant in either of the groups (Supplementary Table 4), and Kaplan–Meier analysis showed no significant difference in survival between responders and non-responders to antidepressant treatment (Supplementary Fig. 1).
Discussion
In this study, we found higher 2-year mortality rates in participants with a depressive disorder, both women and men, compared with participants without a depressive disorder. Among those with a diagnosed depressive disorder, antidepressant treatment was associated with increased mortality in both men and women compared with no antidepressant treatment. However, antidepressant treatment and mortality showed no significant independent association, nor were there any significant differences in survival between responders and non-responders to antidepressant treatment. Depressive disorders were a statistically significant predictor of 2-year mortality in men, with a 24% increased risk of death. Living alone, dementia and heart failure were significantly associated with depressive disorders in both men and women, whereas diabetes showed an inverse association. In women only, age, angina pectoris and visual impairment were associated with depressive disorders, whereas being a widower was inversely associated with depressive disorders in men only.
Having a depressive disorder was associated with an increased risk of death within 2 years for both men and women, consistent with the findings of previous studies on mortality and depressive disorders among older and very old adults. Reference Péquignot, Dufouil, Pérès, Artero, Tzourio and Empana3,Reference Schulz, Beach, Ives, Martire, Ariyo and Kop4,Reference Bergdahl, Gustavsson, Kallin, Von Heideken Wågert, Lundman and Bucht7 However, the present study revealed that having a depressive disorder was a significant predictor of 2-year mortality solely for very old men. Previous studies of gender differences in mortality among older adults with depressive disorders have shown that severe depressive syndromes increase mortality in both men and women, but mild depression increases the risk solely in men. Reference Schoevers, Geerlings, Beekman, Penninx, Deeg and Jonker33 In older men, antidepressant treatment is associated with higher mortality risk, Reference Ryan, Carriere, Ritchie, Stewart, Toulemonde and Dartigues34 with this risk increasing with depression severity; Reference Ryan, Carriere, Ritchie, Stewart, Toulemonde and Dartigues34,Reference Almeida, Alfonso, Hankey and Flicker35 by contrast, in women, only severe depression and lack of treatment has previously been shown to increase mortality risk. Reference Ryan, Carriere, Ritchie, Stewart, Toulemonde and Dartigues34 A previous study specifically of very old adults has likewise indicated potential gender-based differences in mortality among very old men and women. Reference Boström, Hörnsten, Brännström, Conradsson, Nordström and Allard14 Another study found that men did not seek help for depressive disorders to the same extent when the presenting symptoms were male-specific (such as but not limited to irritability, aggression and substance misuse) compared with when they exhibited traditional symptoms. Reference Call and Shafer36 Furthermore, studies have shown that depressive disorders are underdiagnosed among older and very old adults. Reference Bergdahl, Gustavsson, Kallin, Von Heideken Wågert, Lundman and Bucht7,Reference Castel, Shahar, German and Harman-Boehm37 Given these previous findings and the results of the present study, more attention should be paid to establishing robust screening protocols for depressive disorders in older and very old men, to reduce both suffering and mortality.
Previous studies have indicated that antidepressant treatment may increase mortality owing to drug side-effects or drug–drug interactions and medical comorbidities. Reference Sobieraj, Martinez, Hernandez, Coleman, Ross and Berg8,Reference Taylor9 Although the results of this study found no independent association between antidepressant treatment and mortality, further research is needed to explore the potential factors contributing to the differences in survival patterns between those with and without antidepressant treatment. It is possible that these mortality differences are due to different underlying risk factors. A previous large cohort study found no increased risk of mortality among older adults (80+ years) with antidepressant treatment after propensity score matching, Reference Kollhorst, Jobski, Krappweis, Schink, Garbe and Schmedt10 highlighting the need for further research on those treated with antidepressant medication owing to the risk of confounding by indication. There have also been varying results regarding increased mortality associated with different antidepressant medications, Reference Coupland, Dhiman, Morriss, Arthur, Barton and Hippisley-Cox12,Reference Santandreu, Caballero, Gómez-Serranillos and González-Burgos13 with a recent study suggesting higher response rates to newer antidepressant medications among very old adults. Reference Corneliusson, Gustafson and Olofsson16 Therefore, future research should also explore the pharmacodynamics of various antidepressant medications in very old adults. Stand-alone antidepressant treatment is often the only treatment offered to older and very old adults with depressive disorders, Reference Giovannini, Onder, van der Roest, Topinkova, Gindin and Cipriani1 as providers often exclude very old adults from being offered psychotherapeutic services. Reference Tegeler, Beyer, Hoppmann, Ludwig and Kessler38 However, psychological therapy has been identified as an effective treatment for mild to moderate depression in vulnerable younger older adults living at home Reference Tegeler, Beyer, Hoppmann, Ludwig and Kessler38 and has shown better outcomes among older adults compared with working age adults, Reference Saunders, Buckman, Stott, Leibowitz, Aguirre and John39 with no risk of side-effects or drug interactions. Therefore, further resources should be allocated to exploring psychological therapy as a treatment option for very old adults.
A surprising result of this study was that diabetes decreased the odds of depressive disorders for both men and women. Although previous research has found diabetes to increase the risk of depressive disorder in older adults, Reference Andrade, Rocha and Ribeiro40 it is also known that the probability of depressive disorders tends to increase in older age owing to physical illnesses that may restrict autonomy and opportunities for social interaction. Reference Stek, Gussekloo, Beekman, Van Tilburg and Westendorp41 However, it is possible that increased social contact with healthcare services following a diabetes diagnosis might serve as a protective factor against developing depressive disorders, as being recognised and screened for depressive disorders in older age is a crucial factor for positive outcomes. Reference Devita, De Salvo, Ravelli, De Rui, Coin and Sergi42 Although previous studies have shown electroconvulsive therapy and lithium to be efficient treatments for older adults with depressive disorders, Reference Kerner and Prudic43,Reference Leleu, Sánchez-Rico, Abellán, Blanco, Yeim and Chaugne44 future research could further investigate the association found in this study and determine whether early healthcare interventions could provide a cost-efficient and non-invasive way to reduce the disease burden associated with depressive disorders.
The results of this study showed that very old adults with depressive disorders have increased 2-year mortality, with depressive disorders being a predictor of mortality among very old men, indicating a need for urgent measures to reduce mortality and suffering among this demographic. Further research on the effects of antidepressant medication among very old adults is also warranted to ensure the safety of these medications in this demographic.
Strengths and limitations
The strengths of this study include the large sample size and high participation rate, particularly given the high age of the participants. The home visit interviews included all potential participants irrespective of cognitive or physical status or type of residence, resulting in the sample being largely representative. The meticulous diagnostic and medication confirmation processes also represent a strength, as an experienced geriatrician confirmed all diagnoses, and the medication confirmation was conducted in person with all participants. However, there were also some limitations. The duration of treatment with antidepressants was not analysed, and owing to the high age of participants and the consequent drop-out, repeated cross-sectional data were used. Moreover, the study population was confined to northern Sweden and western Finland, limiting the generalisability of our findings, and, as this was a cross-sectional and observational study, causality could not be inferred. Finally, causes of death were not specified; therefore, further investigation of mortality factors is warranted.
Supplementary material
The supplementary material is available online at https://doi.org/10.1192/bjp.2025.10344
Data availability
The research material used in this study and the data and analytic code that support the findings are available upon reasonable request.
Acknowledgements
We thank the Umeå 85+/GERDA participants and their relatives, and all individuals who helped with data collection, for their fundamental contributions to the study over the years.
Author contributions
Y.G. conceptualised, designed and financed the Umeå 85+/GERDA study. B.O., Y.G. and J.N. participated in investigation and data curation. B.O., Y.G. and J.N. provided supervision and guidance, and L.C., N.V. and A.M. were responsible for statistical analysis. N.V. and L.C. wrote the paper with input from all authors. All authors read and approved the final version of the manuscript.
Funding
This work was supported by the Swedish Research Council (Y.G., K2014-99X-22610-01-6), a regional agreement between Umeå University and Västerbotten County Council on cooperation in the fields of medicine, odontology and health (Y.G.), the Research Foundation of the Faculty of Medicine and Odontology at Umeå University (Y.G.), the Swedish Dementia Association (Y.G., B.O., L.C. and J.N.), the Strategic Research Area Health Care Science (B.O.), the European Union and Regional Development Fund (Y.G.), and the Interreg IIIA Mitt-Scandia and the Bothnia-Atlantica Program (Y.G.).
Declaration of interest
None.
eLetters
No eLetters have been published for this article.